Therapeutic Advances in Infectious Disease is a distinguished journal published by SAGE Publications Ltd, dedicated to advancing knowledge in the vital field of infectious diseases and pharmacology. With an impactful Open Access model since 2019, the journal facilitates unrestricted access to a wealth of high-quality research, enabling researchers, clinicians, and educators to stay at the forefront of infectious disease management and treatment. As a recognition of its contribution to the scientific community, the journal holds a prestigious Q1 quartile ranking in both Infectious Diseases and Medical Pharmacology as of 2023, underscoring its influence and relevance in these domains. The journal is positioned favorably within the Scopus rankings, with an impressive standing in the diverse categories of Medicine, emphasizing its commitment to disseminating innovative research. Through a rigorous peer-review process and a broad scope that covers therapeutic advancements, Therapeutic Advances in Infectious Disease serves as an essential resource for anyone involved in combating infectious diseases, offering insights that drive clinical applications and enhance patient care.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

The Canadian Journal of Infectious Diseases & Medical Microbiology, published by HINDAWI LTD, is a pioneering open-access journal focused on advancing the fields of infectious diseases and medical microbiology, with its commitment to disseminating innovative research since 2004. With the ISSN 1712-9532 and E-ISSN 1918-1493, the journal is recognized for its high-caliber contributions, achieving a 2023 Q2 ranking in Infectious Diseases and a Q3 ranking in Medical Microbiology, as per the prestigious Scopus rankings. Offering a global platform for researchers and clinicians, the journal is crucial for fostering collaboration and sharing knowledge across borders, emphasizing its role as a significant resource for addressing pressing health challenges. With an HIndex that indicates an increasing influence in the scientific community, the journal maintains its focus on impactful studies that inform clinical practices and policies, while also being available to a diverse audience through its open-access format. Based in Egypt, the journal looks forward to continuing its impact up to 2024 and beyond, serving as a vital forum for scientific exchange and practical applications in the fight against infectious diseases.

Revista Chilena de Infectologia is an esteemed academic journal dedicated to the field of infectious diseases and public health. Published by the SOC CHILENA INFECTOLOGIA, this journal has been pivotal in disseminating crucial research findings since its inception in 2000. While operating under ISSN 0716-1018 and E-ISSN 0717-6341, it aims to contribute to the understanding of both local and global health issues, particularly within the context of Chile. Currently, it holds a Q4 ranking in both the Infectious Diseases and Public Health, Environmental and Occupational Health categories as of 2023, reflecting its unique position among emerging voices in the field. The journal aspires to foster collaboration among researchers, professionals, and students by offering a platform for innovative studies and discussions that address pressing health challenges. Although it is not an Open Access journal, access options through institutional subscriptions are encouraged for a comprehensive review of its significant contributions to infectious disease research.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

EPIDEMIOLOGY AND INFECTION is a premier open-access journal published by Cambridge University Press, dedicated to advancing the field of epidemiology and infectious diseases. With an ISSN of 0950-2688 and E-ISSN of 1469-4409, this journal has been at the forefront of disseminating impactful research since its inception in 1970. As of 2023, it holds a prestigious Q2 ranking in both the fields of Epidemiology and Infectious Diseases, reflecting its significant contribution to these critical areas of study, with Scopus rankings placing it at #70 in Epidemiology and #163 in Infectious Diseases. The journal aims to publish high-quality, peer-reviewed studies that contribute to our understanding and management of infectious diseases globally. Operating under an open-access model since 2020, EPIDEMIOLOGY AND INFECTION ensures that research is accessible to a wide audience, fostering collaboration and innovation among researchers, professionals, and students alike. With a commitment to excellence, this journal is an essential resource for those looking to stay abreast of the latest developments in epidemiological research and infectious disease management.

INTERNATIONAL JOURNAL OF STD & AIDS is a prominent publication dedicated to advancing the understanding and treatment of sexually transmitted diseases and HIV/AIDS. Published by SAGE Publications Ltd, this esteemed journal has been contributing to the medical community since 1990, with a convergence of studies spanning to 2024. With its ISSN 0956-4624 and E-ISSN 1758-1052, the journal is recognized for its rigorous peer-reviewed research and has successfully positioned itself in the second quartile (Q2) of Dermatology and Public Health, alongside notable rankings in Infectious Diseases and Pharmacology. Currently based in the United Kingdom, this journal serves as a crucial resource for researchers, healthcare professionals, and students, providing a platform for innovative studies and critical reviews that address global health challenges. Although it does not offer Open Access, the journal continues to maintain its reputation as a vital reference point for those invested in the fields of dermatology, public health, and infectious diseases.